Lonapegsomatropin
Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency. Lonapegsomatropin is a prodrug of somatropin.Lonapegsomatropin was approved for medical use in the United States in August 2021.

Medical uses
Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.

References
Further reading
External links
"Lonapegsomatropin". Drug Information Portal. U.S. National Library of Medicine.
Clinical trial number NCT02781727 for "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)" at ClinicalTrials.gov